Merck KGaA

News

Merck unit SpringWorks has claimed EU approval for Ogsiveo, becoming the first approved therapy for desmoid tumours in Europe.

News

Merck KGaA has become the latest drugmaker to partner with Skyhawk Therapeutics on its RNA splicing drug discovery engine.

News

Merck gets another quick return on its $3.9bn SpringWorks takeover with EU approval of Ezmekly for tumours caused by neurofibromatosis type 1.

News

Hopes rise for a new treatment option for people living with lupus, after UCB and Biogen reveal phase 3 data with their anti-CD40L antibody DZP.

News

Imec will demonstrate an ingestible sensor device today that can monitor gut health and could be a valuable tool for research and clinical trials.

News

Merck KGaA has reached an agreement with SpringWorks on a $47-per-share takeover deal that values the US biotech at $3.9 billion.